A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Trial Profile

A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CLARITY
  • Sponsors EMD Serono; Merck Serono
  • Most Recent Events

    • 12 Oct 2017 Results of CLARITY and CLARITY Extension study, presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 12 Oct 2017 Results (n=5763) of pooled data from CLARITY and CLARITY EXTENSION study assessing health state utilities in patients with relapsing remitting multiple sclerosis, presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 07 Sep 2017 According to an EMD Serono media release, Gavin Giovannoni is the lead investigator of the CLARITY studies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top